Partnering Strategy
Open to range of models, Global & Regional Deals, JV, Spin-Offs and Optional Deal Arrangements.
Commercialize across 'pharmerging' markets on our own or with partners
In License differentiated pre-clinical/IND stage assets and progress them through clinical POC/Phase II
Explore co-development opportunities with assets that complement Rhizen programs
Support CMC development and commercial supply activities
Monetize our inflammation assets through global out-licensing to partners with deep TA expertise
Our Partners
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. TG Therapeutics is headquartered in New York City (www.tgtxinc.com)
Curon Biopharmaceutical, founded in June 2018, is a biopharma company with facility in Shanghai focusing on developing next generation anti-cancer therapies
Rhizen – TGTX Alliance
A Template of Our Win-Win Partnering Strategy
Journey from development to commercialization – Focus on Umbralisib
2012: Partnership at IND stage Joint development through Phase 1
- TGTX exercised WW licensing rights for Umbralisib in Sept 2014
- Rhizen retains regional rights, responsible for manufacturing & commercial supply
2021: Poised to transform NHL and CLL
- Relevant Orphan / BTD / Fast Track designation
- Umbralisib commercialized in r/r MZL and FL; poised for approval in r/r & 1st line CLL
- Umbralisib leads TGTX's oncology pipeline and is the backbone for multiple combinations
Both partners’ capabilities have grown across discovery, clinical development and commercialization readiness
